Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Oncology

• Publication date

  2000-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2000.18.5.1058PMID 10694557
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.

  1998cited by this paper
• Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.

  1998cited by this paper
• Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium

  1997cited by this paper
• Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

  1997cited by this paper
• Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1997cited by this paper
• Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

  1994cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

  1991cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper

• Current Therapy for Metastatic Urothelial Carcinoma.

  2021cites this paper
• Cytotoxic Chemotherapy for Advanced Bladder and Upper Tract Cancer

  2021cites this paper
• Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival.

  2017cites this paper
• Management of Bladder Cancer, Role of Chemotherapy and Controversies Surrounding Its Application

  2015cites this paper
• Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum

  2015cites this paper
• Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen

  2014cites this paper
• A Qualitative Study of Breast Cancer Treatment Decisions: Evidence for Five Decision-Making Styles

  2013cites this paper
• Current chemotherapeutic options for the treatment of advanced bladder cancer: a review.

  2013cites this paper
• Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

  2013cites this paper
• A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder

  2013cites this paper
• Current chemotherapeutic strategies against bladder cancer

  2012cites this paper
• Chemotherapy for Metastatic Disease

  2012cites this paper
• Urothelial cancers: using biology to improve outcomes

  2012cites this paper
• Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

  2011cites this paper
• Chemotherapy in advanced bladder cancer: current status and future

  2011cites this paper
• [The role of chemotherapy in the management of bladder cancer].

  2011cites this paper
• Chemotherapy for Metastatic Bladder Cancer

  2011cites this paper
• Experiencia en la preservación de órgano en cáncer de vejiga con infiltración a la capa muscular Experience in organ preservation in bladder cancer with infiltration of the muscular

  2009cites this paper
• Beyond MVAC: New and Improved Chemotherapeutics

  2009cites this paper
• Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.

  2009cites this paper
• Bladder cancer

  2009cites this paper
• Current optimal chemotherapy for advanced urothelial cancer

  2008cites this paper
• Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.

  2008cites this paper
• Bladder preservation: optimizing radiotherapy and integrated treatment strategies

  2008cites this paper
• Management of metastatic bladder cancer

  2008cites this paper
• The evolving role of chemotherapy in advanced urothelial cancer

  2007cites this paper
• Chemotherapy for metastatic or unresectable bladder cancer.

  2007cites this paper
• Urological cancers in clinical practice

  2007cites this paper
• Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

  2007cites this paper
• hemotherapy for Bladder Cancer : reatment Guidelines for Neoadjuvant hemotherapy , Bladder Preservation , djuvant Chemotherapy , and Metastatic ancer

  2007cites this paper
• Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.

  2007cites this paper
• Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

  2007cites this paper
• Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.

  2006cites this paper
• State-of-the-art management of metastatic disease at initial presentation or recurrence

  2006cites this paper
• Bladder-sparing approaches to invasive disease

  2006cites this paper
• Challenges in the treatment of bladder cancer.

  2006cites this paper
• A Phase I Dose Finding Study of Cisplatin, Gemcitabine, and Weekly Docetaxel for Patients With Advanced Transitional Cell Cancer

  2006cites this paper
• Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.

  2006cites this paper
• Systemic chemotherapy for advanced bladder cancer: update and controversies.

  2006cites this paper
• Muscle invasive and metastatic bladder cancer.

  2006cites this paper
• Small-cell carcinoma of the urinary bladder: diagnosis and management

  2006cites this paper
• Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancer.

  2006cites this paper
• Systemic chemotherapy in inoperable or metastatic bladder cancer.

  2006cites this paper
• Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.

  2005cites this paper
• The role of taxanes in the management of bladder cancer.

  2005cites this paper
• Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study

  2005influential citation
• Management of patients with muscle-invasive and metastatic bladder cancer.

  2005cites this paper
• [Effectiveness of neoadjuvant chemotherapy for the patients with locally invasive bladder cancer].

  2005cites this paper
• Chemotherapy for Bladder Cancer

  2005cites this paper
• Bladder cancer discovered by ovarian metastasis: Cytokeratin expression is useful when making differential diagnosis

  2005cites this paper
• Chemotherapy in Locally Advanced and Metastatic Bladder Cancer

  2005cites this paper
• Management of muscle-invasive bladder cancer in the elderly

  2004cites this paper
• A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.

  2004cites this paper
• A Phase II Evaluation of Weekly Paclitaxel Plus Carboplatin in Advanced Urothelial Cancer

  2004cites this paper
• Treatment and care of neurotoxicity from taxane anticancer agents

  2004cites this paper
• Managing taxane toxicities

  2003cites this paper
• New drugs and new approaches in metastatic bladder cancer.

  2003cites this paper
• Overview of bladder cancer trials in the Radiation Therapy Oncology Group

  2003cites this paper
• Metastatic Bladder Cancer: Role of Chemotherapy and New Agents

  2003cites this paper
• Overview of bladder cancer trials in the European Organization for Research and Treatment

  2003cites this paper
• Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group

  2003cites this paper
• Overview of bladder cancer trials in the European Organization for Research and Treatment

  2003cites this paper
• Overview of gemcitabine triplets in metastatic bladder cancer.

  2003cites this paper
• Management of toxicities associated with the administration of taxanes

  2003cites this paper
• Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy

  2003cites this paper
• Progress in the chemotherapy of metastatic cancer of the urinary tract

  2003influential citation
• [Advanced bladder cancer: new therapeutic strategies].

  2003cites this paper
• Toxicities of the platinum antineoplastic agents

  2003cites this paper
• Bladder cancer.

  2002cites this paper
• Novel gemcitabine-containing triplets in the management of urothelial cancer.

  2002cites this paper
• The role of systemic chemotherapy in the management of muscle-invasive bladder cancer.

  2002cites this paper
• [Chemotherapy of locally advanced T4 and metastatic N+, M+ bladder tumors].

  2002cites this paper
• The present and future of combination chemotherapy in bladder cancer.

  2002cites this paper
• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  2002cites this paper
• Chemotherapy in Metastatic Urothelial Cancer

  2002cites this paper
• Developing therapies for advanced bladder cancer

  2002influential citation
• Current and future perspectives in advanced bladder cancer: is there a new standard?

  2002cites this paper
• Current and future perspectives in advanced bladder cancer: is there a new standard?

  2002cites this paper
• Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

  2002cites this paper
• Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

  2001cites this paper
• Blasencarcinome und Carcinome des Übergangsepithels

  2001cites this paper
• Treatment of metastatic urothelial cancer in the post-MVAC era

  2001cites this paper
• Recent developments in chemotherapy for bladder cancer.

  2001cites this paper
• Locally advanced and metastatic bladder cancer

  2001cites this paper
• New chemotherapy combinations for advanced bladder cancer

  2001cites this paper
• Transitional cell carcinoma of the bladder: New approaches to the treatment of advanced disease

  2001cites this paper
• Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells.

  2001cites this paper
• Second-line treatment of advanced transitional cell carcinoma of the urothelial tract

  2001cites this paper
• Combination P aclitaxel, C arboplatin, a nd G emcitabine I s an A ctive T reatment f or A dvanced U rothelial C ancer

  2001cites this paper
• Chemotherapie des metastasierten Blasenkarzinoms

  2001cites this paper
• Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.

  2000cites this paper
• Paclitaxel and carboplatin in bladder cancer: recent developments.

  2000cites this paper
• Bladder cancer

  1992cites this paper